Is Canntab Therapeutics Limited (CTABF) a Buy, Sell, or Hold?
OTC : CTABF
Canntab Therapeutics Limited
$0.0001 USD
$0 (0.0%)
- Volume
- 2K
- Average Volume
- 1.03K
- Market Capitalization
- $3.89K
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.01
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.57
Company Overview
OTC
Richard C. Goldstein
Drug Manufacturers - Specialty & Generic
Healthcare
CTABF
N/A
CA
USD
Liquidity Metrics
-5.91
0.57
0.38
0.27
0.00
Sales & Valuation
$293.36K
0.02
-0.02
0.00
-0.08
Profitability
-$0.0978
-$3.69M
-1257.55%
-1257.55%
-376.92%
-129.35%
P/E Metrics
0.00
0.00
0.00
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
-39.49
3/9
-$2.78M
$953.54K
$3.11M
-$2.53M
Key Metrics (TTM)
$1.15M
3.94
-0.46
0.57
-376.92%
-230.41%
-69333.59%
-53460.59%
358 days
Company Executives
| Name | Title |
|---|---|
| Barry Polisuk | Secretary & Independent Director |
| Eric Malinski | Director of Marketing |
| Joshi Laxminarayan | Chief Scientific Officer |
| Richard C. Goldstein | Interim Chief Executive Officer, Co-Founder, Chief Financial Officer & Director |
Poll Results
No votes yet today — be the first to share your view!
About Canntab Therapeutics Limited (OTC:CTABF) Stock
Canntab Therapeutics Limited is a Canadian phytopharmaceutical firm dedicated to pioneering the research and development of sophisticated, pharmaceutical-grade cannabinoid preparations. The company manufactures various oral cannabis medications, including extended-release cannabinoid pills and pellets, rapidly acting cannabidiol formulations, multi-layered modified-release options, quick-dissolving flash-melt products, and dual-layer cannabinoid tablets. These offerings target a broad spectrum of health issues, such as sleep disturbances, post-traumatic stress disorder, social anxiety, various addictions, arthritis, chronic pain, appetite loss and pain linked to cancer therapies, and as an aid in managing dependency on opioids and other painkillers. Canntab Therapeutics Limited operates fr ... om its base in Markham, Canada.
Frequently Asked Questions
-
What is the current Canntab Therapeutics Limited (CTABF) stock price?
-
Canntab Therapeutics Limited(OTC:CTABF) stock price is $0.0001 in the last trading session. During the trading session, CTABF stock reached the peak price of $0.0073 while $0.0001 was the lowest point it dropped to. The percentage change in CTABF stock occurred in the recent session was 0.0% while the dollar amount for the price change in CTABF stock was $0.
-
CTABF's industry and sector of operation?
-
The OTC listed CTABF is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of CTABF?
-
Barry Polisuk | Secretary & Independent Director
Eric Malinski | Director of Marketing
Joshi Laxminarayan | Chief Scientific Officer
Richard C. Goldstein | Interim Chief Executive Officer, Co-Founder, Chief Financial Officer & Director
| -
How many employees does CTABF have?
-
Number of CTABF employees currently stands at None. CTABF operates from 223 Riviera Drive, Markham, ON L3R 5J6, CA.
-
Link for CTABF official website?
-
Official Website of CTABF is: https://canntab.ca
-
How do I contact CTABF?
-
CTABF could be contacted at phone #None and can also be accessed through its website. CTABF operates from 223 Riviera Drive, Markham, ON L3R 5J6, CA.
-
How many shares of CTABF are traded daily?
-
The average number of CTABF shares traded daily for last 3 months was 1.03K.
-
What is the market cap of CTABF currently?
-
The market value of CTABF currently stands at $3.89K with its latest stock price at $0.0001